GlassScriptPhysician profile
Michael A Lapuente
NPI 1295761351
$14,241.83
in general payments reported to CMS, 2019-2025
42 companies · $3,386 in 2025
The $3,386 reported for 2025 was more than what 79% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,046 · 2020: $1,414 · 2021: $857 · 2022: $1,400 · 2023: $2,669 · 2024: $2,469 · 2025: $3,386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,279 · Consulting Fee: $131 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,279.26 |
| Consulting Fee | $131.16 |
| Education | $114.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,348.05 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $1,803.17 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,753.43 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $1,144.09 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Genzyme Corporation | $766.44 | 2019-2025 | |
| Grifols USA, LLC | $575.62 | 2019-2025 | Xembify, Gamunex-C |
| Novartis Pharmaceuticals Corporation | $533.24 | 2019-2025 | |
| Pfizer INC. | $525.29 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $485.90 | 2021-2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $474.27 | 2020-2025 | Takhzyro, Cuvitru, Eohilia |
| Ars Pharmaceuticals Operations, INC. | $424.51 | 2025 | Neffy |
| Amgen INC. | $358.19 | 2021-2025 | Tezspire |
| Kaleo, INC. | $354.76 | 2019-2024 | Auvi-Q |
| Genentech USA, INC. | $338.42 | 2019-2025 | Xolair |
| Pharming Healthcare, INC. | $296.08 | 2019-2025 | Ruconest |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $248.21 | 2019-2025 | |
| Alk-Abello, INC | $240.94 | 2019-2020 | |
| Phadia US INC. | $154.13 | 2020-2023 | Immunocap |
| Regeneron Pharmaceuticals, INC. | $144.11 | 2025 | Dupixent |
| Octapharma USA, INC. | $137.12 | 2019-2024 | Panzyga |
| Adma Biomanufacturing LLC | $131.16 | 2024-2025 | |
| Aytu Biopharma, INC. | $122.79 | 2022-2025 | Karbinal |
| Teva Pharmaceuticals USA, INC. | $87.39 | 2020-2022 | |
| Abbvie INC. | $82.56 | 2023-2024 | |
| Hikma Pharmaceuticals USA | $82.44 | 2023-2024 | Ryaltris |
| Jubilant Hollisterstier LLC | $76.16 | 2023 | |
| Ionis Pharmaceuticals, INC. | $65.55 | 2025 | Dawnzera |
| Cycle Pharmaceuticals INC | $63.33 | 2024-2025 | Sajazir |
| Incyte Corporation | $62.27 | 2024-2025 | Opzelura |
| Covis Pharma Gmbh | $53.70 | 2021 | |
| Galderma Laboratories, L.P. | $42.61 | 2025 | Nemluvio |
| Aimmune Therapeutics, INC. | $39.19 | 2021 | |
| Uswm, LLC | $36.00 | 2021 | |
| Leo Pharma INC. | $31.12 | 2022 | |
| Siemens Medical Solutions USA, INC. | $23.95 | 2025 | Immulite 1000 Immunoassay System |
| Gc Biopharma USA, INC. | $21.59 | 2025 | Alyglo |
| Lilly USA, LLC | $20.36 | 2025 | Taltz, Ebglyss |
| Seqirus USA INC | $19.78 | 2025 | Flucelvax |
| Circassia INC. | $19.30 | 2019 | |
| Shire North American Group INC | $19.24 | 2019 | |
| Azurity Pharmaceuticals, INC. | $18.67 | 2025 | Alvesco |
| Mdd US Operations, LLC | $16.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lapuente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.